Page last updated: 2024-10-24

carvedilol and Hepatorenal Syndrome

carvedilol has been researched along with Hepatorenal Syndrome in 2 studies

Hepatorenal Syndrome: Functional KIDNEY FAILURE in patients with liver disease, usually LIVER CIRRHOSIS or portal hypertension (HYPERTENSION, PORTAL), and in the absence of intrinsic renal disease or kidney abnormality. It is characterized by intense renal vasculature constriction, reduced renal blood flow, OLIGURIA, and sodium retention.

Research Excerpts

ExcerptRelevanceReference
" First-line therapies include carvedilol or propranolol to prevent variceal bleeding, lactulose for hepatic encephalopathy, combination aldosterone antagonists and loop diuretics for ascites, and terlipressin for hepatorenal syndrome."5.41Diagnosis and Management of Cirrhosis and Its Complications: A Review. ( Parikh, ND; Tapper, EB, 2023)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (50.00)24.3611
2020's1 (50.00)2.80

Authors

AuthorsStudies
Tapper, EB1
Parikh, ND1
Mandorfer, M1
Reiberger, T1

Reviews

2 reviews available for carvedilol and Hepatorenal Syndrome

ArticleYear
Diagnosis and Management of Cirrhosis and Its Complications: A Review.
    JAMA, 2023, 05-09, Volume: 329, Issue:18

    Topics: Adult; Ascites; Carvedilol; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Hepatic Enc

2023
Beta blockers and cirrhosis, 2016.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2017, Volume: 49, Issue:1

    Topics: Acute Kidney Injury; Adrenergic beta-Antagonists; Ascites; Carbazoles; Carvedilol; Esophageal and Ga

2017